Inflammatory bowel disease (IBD) is a complex autoimmune disease with dysfunction in pattern-recognition responses, including within the NLR family. Nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) is a unique NLR with regulatory and anti-inflammatory functions resulting in protection from IBD in mouse models. NX-13 is an orally active, gut-restricted novel drug candidate that selectively targets and activates the NLRX1 pathway locally in the gut. In vitro and in vivo efficacy of NLRX1 activation by NX-13 was examined. Oral treatment with NX-13 alleviates disease severity, colonic leukocytic infiltration, and cytokine markers of inflammation in three mouse models of IBD (dextran sulfate sodium, Mdr1a−/−, and CD45RBhi adoptive transfer). Treatment of naive CD4+ T cells with NX-13 in vitro decreases differentiation into Th1 and Th17 subsets with increased oxidative phosphorylation and decreased NF-κB activation and reactive oxygen species. With stimulation by PMA/ionomycin, TNF-α, or H2O2, PBMCs from ulcerative colitis patients treated with NX-13 had decreased NF-κB activity, TNF-α+ and IFN-γ+ CD4+ T cells and overall production of IL-6, MCP1, and IL-8. NX-13 activates NLRX1 to mediate a resistance to both inflammatory signaling and oxidative stress in mouse models and human primary cells from ulcerative colitis patients with effects on NF-κB activity and oxidative phosphorylation. NX-13 is a promising oral, gut-restricted NLRX1 agonist for treating IBD.
Over 3 million people in America and 5 million worldwide suffer from inflammatory bowel disease (IBD). This widespread and debilitating illness results in decreased quality of life and significant healthcare related costs (1). The underlying immune dysfunction in Crohn disease (CD) (2, 3) and ulcerative colitis (UC) (4, 5) is with involvement of both innate and adaptive immunity culminating in a perturbed immune tolerance to the gut microbiome and other environmental factors. Despite this complexity, current therapeutics are unrefined steroids, immunosuppressants, and neutralizing Abs to single cytokines such as TNF-α. Although current treatments for IBD have improved (6, 7), these therapies remain modestly successful with adverse side effects, including immunosuppression, increased risk for infection, malignancies, and death. Thus, an unmet clinical need exists for novel targets capable of restoring immune tolerance and controlling the wide array of immune responses.
NLRs are a family of cytosolic pattern-recognition receptors that function in surveillance of metabolic stress, discrimination between pathogenic bacteria versus beneficial symbionts, and recognition of inflammatory signaling (8–12). Genetic polymorphisms in several NLRs have been described in IBD such as NLRC1 (NOD1) and NLRC2 (NOD2) (13–15). Although NOD1 and NOD2, in addition to inflammasome-associated NLRs, are well-characterized to contribute to human disease, a smaller class of negative regulatory NLRs remain relatively unknown. Indeed, genetic abnormalities in these well-characterized NLR genes are linked to IBD pathogenesis (16–19). This smaller family of NLRs comprises NLRX1, NLRP12, and NLRC3 and has shown potent effects in the attenuation of inflammation in nonclinical models of autoimmune and infectious disease. NLRX1 regulates inflammation and IFN production in response to pathogens (20–23) and antagonizes NF-κB (20, 23, 24). However, many of these preclinical studies focus solely on the worsening of disease in loss-of-function designs. The ability to modulate function by pharmacologic activation of the receptor, the prevalence of function-disrupting mutations, and native expression patterns in response to inflammation is unknown in human disease.
NLRX1 is a mitochondria-associated receptor involved in downregulating inflammation during bacterial and viral exposure, acute noninfectious colitis, colorectal cancer, and chronic pulmonary disease (20, 22, 23). NLRX1−/− mice with dextran sulfate sodium (DSS) colitis have significantly worse disease activity associated with more severe gut mucosal inflammation and fibrosis when compared with their wild-type (WT) counterparts (25). Colonic NLRX1 expression is significantly suppressed in colons of mice with colitis (26). RNA-seq data from colons of WT and NLRX1−/− mice unveil that loss of NLRX1 during colitis causes overzealous inflammatory chemokine and cytokine signaling (>10-fold increase) in myeloid and epithelial cell response elements such as Il-6, Tnf, Ifng, Il-21, and Mcp1. Previously, we demonstrated that the deficiency of NLRX1 worsens inflammatory responses in vitro in both CD4+ T cells and epithelial cells of mice and shifts the metabolic preferences of cells. When the metabolic differences are prevented, the immune effects resulting from the loss of NLRX1 are abrogated (25) both in vitro and in vivo that are integrated with changes in inflammation-associated bacterial taxa within the colonic microenvironment (27).
In line with these beneficial preclinical responses in IBD, we have developed 1, 3, 5-tris (6-methylpyridin-2-yloxy) benzene (NX-13), as an orally active, gut-restricted, NLRX1-activating therapeutic with limited systemic exposure for the treatment of IBD. NX-13 was generated by medicinal chemistry-based optimization of novel scaffolds designed to target the previously categorized binding pocket of NLRX1. In preliminary safety and pharmacokinetic studies, NX-13 is gut-restricted with no effects on systemic hematology parameters and a “no observable adverse effect level” ≥1000 mg/kg (28). Following through in silico testing of affinity, safety, and pharmacokinetics, NX-13 was synthesized to characterize its efficacy in the treatment of IBD. To our knowledge, this manuscript provides the first evidence for NX-13 as a promising immunometabolic therapeutic in three models of IBD and primary cells from human UC patients.
Materials and Methods
WT and Rag2−/− mice were used on a C57BL/6 background. Mdr1a−/− were used on an FVB background. All procedures and experiments were approved by an institutional animal care and use committee. Experimental groupings were age-, gender-, and litter-matched with equal distribution to groups in cohoused conditions. For DSS experiments, 8-wk-old WT mice were administered DSS in drinking water for 7 d. Mice were scored daily for disease activity. For adoptive transfer experiments, 7-wk-old Rag2−/− mice were injected with 4 × 105 naive CD4+ T cells (CD45RBhi) per mouse by i.p. injection. Mice were scored weekly posttransfer for disease activity for 8 wk. For Mdr1a−/− experiments, Mdr1a−/− mice were started on treatment at 4 wk of age and continued treatment through 10 wk of age. Mice were scored weekly. Disease activity was scored on a range from 0 to 4, encompassing parameters pertaining to rectal inflammation, stool consistency, presence of blood in stool, and overall appearance/behavior. General assignment of score corresponded to 0, no symptoms; 1, soft/loose/watery stool; 2, blood or moderate rectal inflammation; 3, blood and moderate or greater inflammation; and 4, severe gastrointestinal (GI) symptoms with reduced activity or weight loss. NX-13 treatments, or vehicle control, were administered by orogastric gavage daily for the duration of each experiment.
CD4+ T cell culture
Naive CD4+ T cells were obtained from spleens of WT mice by magnetic sorting of a cellular suspension of splenocytes. Naive CD4+ T cells were cultured in IMDM supplemented with FBS within anti-CD3/anti-CD28 coated 96 well plates. Cells were differentiated into Th1 or Th17 cells by cytokine mixture: IL-12 (10 ng/ml) or anti–IL-4 (500 ng/ml); or IL-6 (10 ng/ml), TGF-β (5 ng/ml), or anti–IL-4 (500 ng/ml), respectively. During differentiation, cells were treated with NX-13. After 48 h, cells were stimulated with PMA (5 ng/ml) and ionomycin (500 ng/ml) (PMA/I) for 6 h. After stimulation, cells were assayed for cellular phenotype by flow cytometry, gene expression by quantitative RT-PCR (qRT-PCR), proliferation by CFSE staining, or NF-κB, reactive oxygen species (ROS), lactate dehydrogenase (LDH) activity, and glucose uptake, according to manufacturer’s instructions.
Lamina propria lymphocytes were obtained from colons by collagenase/DNase digestion followed by purification by Percoll gradient. Cultured cells were obtained directly from culture. Cells were washed and stained for extracellular Ags (CD45, CD3, CD4, CD8, CD25, and Gr1). Cells were then fixed and permeabilized for staining of intracellular Ags (IFN-γ, Tbet, IL-10, FOXP3, IL-17, RORγT, and IL-4). Data were acquired on a BD FACSCelesta II and analyzed using BD FACSDiva version 9.0 (BD Biosciences).
Colon or cells were homogenized within RLT buffer. RNA was isolated from homogenate by RNAeasy Mini Kit, according to manufacturer’s instructions. From RNA, cDNA was produced by iScript reverse transcriptase. qRT-PCR was conducted with SYBR Green Master Mix. Starting quantity was calculated according to standard curve and normalized to β-actin, as previously described.
Colons were fixed within 10% buffered formalin, embedded in paraffin, sectioned, and stained with H&E for examination. Colons were scored (0–4) for leukocytic infiltration, mucosal thickening, and epithelial erosion by blinded pathologist.
PBMCs were isolated from fresh whole blood of male and female UC patients. PBMCs were separated by LeucoSep tube (Greiner Bio-One), and remaining RBCs were lysed by hypotonic lysis. Isolated cells were treated with NX-13 (0, 50, 100, and 500 nM). Cells were stimulated by TNF-α (0.5 ng/ml) for 24 h, hydrogen peroxide (1 mM) for 24 h, or PMA/I for 6 h. Cytokine responses were measured by Luminex, and NF-κB activity was measured by TransAM NF-κB p65 Kit (Active Motif).
Data are presented as mean ± SEM. Quantitative data were analyzed using ANOVA, followed by the Scheffe multiple-comparisons test. ANOVA was performed using the general linear model procedure of SAS (SAS Institute, Cary, NC). Statistical significance was determined at p < 0.05.
NX-13 modulates CD4+ T cell differentiation and metabolism
NX-13 is a symmetric triphenyl compound designed to activate NLRX1 in the GI tract. By Cellular Thermal Shift Assay, NX-13 has in situ binding effects on the stability of NLRX1 at concentrations below 100 nM, with an estimated EC50 of 58 nM (Fig. 1). As NLRX1 has previously been associated with immunometabolic effects in CD4+ T cells in IBD (25), the differentiation of naive CD4+ T cells was assessed in the presence of NX-13. Treatment with NX-13 significantly decreased the differentiation of Th1 (Fig. 2A) and Th17 (Supplemental Fig. 1) at 0.05 μM, with a dose response and suppressive effect observed down to 0.005 μM. The effect on CD4+ T cell differentiation was observed to be dependent on the presence of NLRX1, whereby CD4+ T cell deficient in NLRX1 did not respond to NX-13 treatment (Supplemental Fig. 1). Reduction of Th1-phenotyped cells corresponded with a marked decrease in IFN-γ production (Fig. 2G, 2H). In line with the previously described metabolic functions of NLRX1 activation, NX-13 decreased LDH activity (Fig. 2B) and glucose uptake (Fig. 2C) in in vitro–differentiated Th1 cells paired with a decrease in proliferation (Fig. 2D, 2I). No effect on cell death or apoptosis was observed (Supplemental Fig. 1). NX-13 also decreased NF-κB activity (Fig. 2E) and intracellular ROS levels (Fig. 2F), two inflammatory signaling elements inhibited by NLRX1 activation. Additionally, after the observation of effects on metabolism and ROS levels, we further characterized the effects of NX-13 treatment by qRT-PCR of in vitro–differentiated Th1 cells. Although NX-13 is associated with increased oxidative phosphorylation (Fig. 2J–M), it is also associated with increased expression of antioxidant enzymes, including Gpx1, Gstm1, and Txnrd1 (Fig. 2N–P). Meanwhile, Eno1, a marker of anaerobic glycolysis activity and a moonlighting enzyme associated with inflammatory signaling, is decreased by NX-13 (Fig. 2Q).
NX-13 reduces inflammation in a model of DSS colitis
Upon validation of NLRX1-mediated activity in vitro, NX-13 was tested in a DSS model of colitis to characterize its therapeutic efficacy and underlying immunological changes induced by NX-13 in the gut. Oral treatment with NX-13 reduced disease activity index (Fig. 3A), a summarized score encompassing diarrhea, rectal bleeding, rectal inflammation, and overall activity, with significant reduction retained throughout the 7-d DSS period, at dosages as low as 1 mg/kg. Similar trends were observed microscopically with reductions in leukocytic infiltration, epithelial erosion and mucosal thickening recorded at 1 mg/kg and higher upon examination of colon (Fig. 3B–D). Reduction in leukocytic infiltration was observed at both the mucosal and submucosal levels, whereas NX-13 also protected against ulceration and loss of crypt architecture (Fig. 3K, 3L). Treatment with NX-13 resulted in an increased colonic expression of Nlrx1 (Supplemental Fig. 2), with significant increases observed at 10 and 20 mg/kg. Fecal calprotectin, a clinical biomarker for intestinal inflammation and treatment response and remission, was decreased by NX-13 treatment on day 7 (Fig. 3E). Notably, NX-13 treatment resulted in a greater reduction of fecal calprotectin in the DSS model when compared with current UC therapeutics (Supplemental Fig. 3). By flow cytometry immunophenotyping, 1 mg/kg oral NX-13 significantly decreased Th1, Th2, and Th17 (Fig. 3F–H) locally within the colon. A significant decrease in neutrophils was observed at 10 mg/kg and higher, with a noted suppressive trend at lower dosages (Fig. 3I). In contrast, CD25+ regulatory T cells (Tregs) were significantly increased at the highest test dosage, 20 mg/kg, and slightly increased at lower dosages (Fig. 3J). Similar trends in cellular populations were also observed based on percentage of CD45+ cells (Supplemental Fig. 2). When NX-13 was dosed to unchallenged mice, splenic immune cell populations were unchanged (Supplemental Fig. 2), suggestive of local action.
NX-13 maintains immune homeostasis after CD45RBhi adoptive transfer
Based on the in vitro response to NX-13 in CD4+ T cells, its therapeutic efficacy was also assessed in the CD45RBhi adoptive transfer model of IBD. Oral NX-13 treatment significantly reduced signs of disease posttransfer with reduction of overall disease activity (Fig. 4A). Significant reductions in colonic histopathology parameters (Fig. 4B–D) were similarly observed with NX-13 with notable decreases in leukocytic infiltration and mucosal thickening (Fig. 4E, 4F). In an environment of altered immune tolerance, NX-13 decreased Th1 and Th17 cells, whereas the number of CD25+ Tregs was unchanged (Fig. 4G–I). Reduced neutrophils were also observed in the colonic lamina propria of NX-13–treated mice (Fig. 4J). In regards to the percentage of CD45+ cells, similar trends were observed in the proportion of Th1 and neutrophil cells, whereas the proportion of Tregs was increased (Supplemental Fig. 2).
Therapeutic efficacy of NX-13 in an Mdr1a−/− model of colitis
The knockout of Mdr1a was used as a spontaneous model of severe colitis. Similar to other models of colitis, oral NX-13 treatment results in an early reduction of inflammation that is maintained throughout the course of the experiment in Mdr1a−/− (Fig. 5A). By histopathology, NX-13 reduces the occurrence of crypt destruction and structural abnormalities with reduced infiltration of neutrophils and eosinophils (Fig. 5B, 5C). Cellular reductions in inflammation were confirmed by flow cytometry by observation of reduced Th1 cells and neutrophils and increased proportion of IL-10–producing Tregs in the colonic lamina propria (Fig. 5D–F). Because of a decrease in total immune cell infiltration in the colon, Th1 and neutrophil numbers were also significantly reduced, whereas the total number of Tregs were unchanged (Supplemental Fig. 2). At the transcriptional level, colonic expression of Ifng and Tnf was reduced with oral NX-13 treatment (Fig. 5G, 5H).
In vivo validation of NX-13–induced metabolic changes in Mdr1a−/− colitis
Upon demonstration of therapeutic efficacy, we examined local biomarkers of NX-13 activity. A panel of cytokines was used to determine changes in inflammatory response, representative of the effects of NX-13 (Fig. 6A). Notable cytokines prominent in IBD, such as TNF, IL-6, and MCP1, were decreased by NX-13, whereas an increase in IL-10 was observed in NX-13–treated mice. Additional cytokines with a lower degree of characterization in IBD, such as CXCL1, MIP1α, IL-9, and IL-1α were also decreased, indicating an ability of NX-13 to extend anti-inflammatory properties beyond a single cytokine. Next, expression of metabolic genes was measured in Mdr1a−/− mice after treatment with 10 or 20 mg/kg NX-13 to determine local metabolic biomarkers of NX-13 activity. In a similar manner to that observed in vitro, NX-13 resulted in an increase in markers of oxidative phosphorylation, including the mitochondrially encoded Nd3 and Co3, and rate-limiting enzyme, Ogdh (Fig. 6B–D). In contrast, Eno1 was decreased by NX-13 (Fig. 6E). The change in oxidative phosphorylation was paired with increased expression of antioxidant enzymes, Gpx1 and Gstm1 (Fig. 6F, 6G). In an activity-based assay, colonic glutathione peroxidase was also observed to be increased with NX-13 (Fig. 6H), with similar increases observed in colonic glutathione levels (Fig. 6I). Similar to the DSS model, these cytokines and metabolic changes correlated to increased colonic expression of Nlrx1 at 10 and 20 mg/kg (Supplemental Fig. 2).
NX-13 reduces inflammation and alters NLRX1 signaling in PBMCs from UC patients
Based on the efficacy of NX-13 in mouse models of IBD, the translational value and potency of response to NX-13 treatment was tested within PBMCs from moderate to severe UC patients. At concentrations of 0.01 μM and higher, NX-13 significantly reduced TNF-α– and IL-4–producing cells after 24 h of culture (Fig. 7A, 7B). Meanwhile, at 0.05 μM and above, IL-10–producing cells were increased, and IFN-γ–producing cells were decreased (Fig. 7C, 7D). NX-13 reduces both NF-κB and ROS production upon stimulation with PMA/I, TNF, or hydrogen peroxide (Fig. 7E, 7F). Importantly, NX-13 greatly reduced ROS production with oxidative stress caused by hydrogen peroxide. Additionally, NX-13 decreased inflammatory cytokines implicated in IBD, including IL-8, MCP1, and IL-6 upon stimulation with PMA/I or TNF (Fig. 7G–I). These results suggest a translatable potency of NX-13 between mice and humans, with clear therapeutic benefit ex vivo for the reduction of inflammation in primary cells from UC.
NX-13 is a promising immunometabolic oral, gut-restricted therapeutic for CD and UC that is effective at reducing inflammation in DSS, adoptive transfer, and Mdr1a−/− mouse models of IBD plus in in vitro studies using primary murine and human cells. Through the activation of NLRX1, NX-13 increases oxidative phosphorylation in immune cells resulting in a decrease in the inflammation-associated anaerobic glycolysis. However, despite the increase in oxidative metabolism, NX-13 treatment decreases cellular ROS through activation and increased expression of antioxidant enzymes. Downstream of NLRX1, these immunometabolic changes result in decreased NF-κB activity and lower production of inflammatory cytokines such as TNF-α and IFN-γ. Both in vitro and in vivo, these signaling changes result in lower levels of Th1 cells. Oral NX-13 treatment reduces colonic lesions and overall disease severity at a dosage as low as 1 mg/kg, indicating a high potential for further development as an investigational new drug for CD and UC.
The concept that immune and metabolic pathways have important codependencies has clear relevance to the understanding of disease and therapeutic development, particularly IBD with diminished activity of the electron transport chain and lower ATP levels observed in the inflamed GI tract (29, 30). Effector CD4+ T cells (Th1 and Th17) drive glycolytic responses to produce energy quickly (31). Immune cells unable to establish fatty acid metabolism can show insensitivity to regulatory and suppressive signals (32). Our data suggest that NLRX1 acts as a key regulator of metabolic reprogramming within immune cells with greater oxidative phosphorylation by NX-13 treatment in line with the previously described augmentation of glycolytic flux and decreased substrate-switching capability displayed by NLRX1-deficient cells (25). Indeed, NLRX1 directly influences the maturation of mitochondrial RNA for important oxidative phosphorylation enzymes (33). Further, Eno1, which is decreased by NX-13, is connected to TNF-α, IL-1β, and IFN-γ, is increased in colonic tissues, and may serve as an important Ag in IBD with 50% of UC and CD patients presenting with serum anti-ENO1 Abs (34, 35). The remaining question was whether the increased oxidative phosphorylation would lead to an increase in intracellular ROS and activation of inflammatory pathways. However, activation of NLRX1 by NX-13 leads to a decrease in ROS that is paired with increased antioxidant enzyme activity. Because of its previous connection to the regulation of MAVS, NLRX1 could be acting as an important switch through c-Abl that would serve to activate GPX1 (36, 37). The role in this regulation merits further exploration. With previous connections to the prevention of oxidative stress (25, 38) and the described data in this study, including increases to Gpx1, Gstm1, and Txnrd1, NLRX1 is a potent controller of the cellular oxidative state. Meanwhile, impaired function of these enzymes has been linked to enhanced susceptibility to IBD and leukocytic infiltration in colons of patients (39–41).
The implication of ROS in the NLRX1 pathway extends beyond the metabolic effects but the downstream signaling. Among other molecules, ROS are proposed to be a key mediator in the downstream effects of NLRX1 on NF-κB and potentially other inflammatory pathways including the phosphorylation of ERK1 and ERK2 leading to upregulation of MAPK activity (42). Although cytoplasmic NLRX1 has direct effects on NF-κB activity, the control of Gpx1, and other antioxidant enzymes may provide further inhibitory support of the pathway as IKKα can be inhibited by the decrease in hydrogen peroxide levels (43). Conversely, NF-κB activity has also been linked to antioxidant enzyme transcription, suggesting a potential coregulation and feedback in this linkage in parallel to NF-κB–mediated upregulation of ROS producers (44). Dysfunction of this feedback may be important in the pathogenesis of IBD and a cause of the increased intestinal oxidative stress observed in UC and CD (45). Additionally, GPX1 activity has been connected to a decreased ability of TNF to activate expression of VCAM and ICAM molecules (46), which would lead to further support of in vivo anti-inflammatory effects locally in the GI tract, and serve as a mechanistic link for the observed decreased leukocytic infiltration observed in the three models of IBD. Although current data support a lack of effect on systemic immune profiles (28), risk for infection remains a concern in the development of immune-targeted therapeutics. The immunometabolic effects induced by NX-13 may support specific antiviral responses through a depletion of lactate and modulation of the overall cellular energy phenotype. Many of the viral responses connected to NLRX1 have been through its interaction with MAVS; however, MAVS is also highly responsive to metabolic change with recent publications linking high lactate to impaired MAVS and Type I IFN production (47) as well as the necessity of O-GlcNAcylation in MAVS signaling (48). Therefore, the metabolic change combined with NLRX1 activation provide a balance in antiviral signaling. However, additional studies on the effect of NX-13 on both the susceptibility and severity of bacterial and viral infections is needed.
Via control of NF-κB, it is proposed that NLRX1 activation influences a wide array of cytokine responses. Based on the presented findings, oral NX-13 treatment provides anti-inflammatory control over a number of cytokines within the colonic mucosa. These cytokines cover a broad range of functions including potent inflammatory mediators of activation and differentiation (TNF and IL-6), neutrophil and monocyte chemokines (MCP1 and CXCL1), as well as those with newly emergent functions in IBD (MIP1α, IL-9, and IL-1α). Recently, CXCL1 has been identified as a differentiator between responders and nonresponders clinically (49) and IL-9 positively correlated to clinical scores, including mucosal healing and endoscopic appearance in UC (50), whereas changes in MIP1α and IL-1α indicate a potential involvement of myeloid cells in the response to NX-13 treatment (51).
As regulators of many of these molecular changes, this manuscript largely focuses on the effect of NX-13 in CD4+ T cells because of their role in the pathogenesis and chronicity of IBD and the previous implication of NLRX1 in this cell type. NX-13 shows a direct ability to decrease effector CD4+ T cells, including Th1 and Th17 cells. Recent evidence on the dual regulation of these cell types (52), along with the development of anti–IL-23 Abs (53), which serve to suppress both Th1 and Th17 differentiation, support that the potential downmodulation of these cell types independently can reduce GI inflammation in IBD. Based on prior knowledge of NLRX1 and therapeutic efficacy across mouse models of IBD, NX-13 is likely to also induce direct effects on epithelial and myeloid cells, although currently unexplored. Given the shared immunometabolic pathways in each of these cell types, these direct effects would be supportive of the overall anti-inflammatory nature of NX-13 treatment.
Combined with the described therapeutic efficacy in this manuscript, NX-13 is safe up to oral dosages of 1000 mg/kg in preliminary safety studies in rats (28). This benign safety profile is mediated in part by gut-restricted pharmacokinetics, with local colonic concentrations over 1000-fold higher than those in plasma (28). NX-13 is effective in vivo at oral dosages as low as 1 mg/kg, with in vitro responses below 100 nM. With a wide therapeutic window permitted by this large safety margin, NX-13 is a prime candidate for advancement into investigational new drug–enabling studies and clinical testing in UC and CD patients. By immunometabolic mechanisms targeting enhanced oxidative phosphorylation and controlled ROS levels, NLRX1 activation is an innovative first-in-class strategy for the treatment of autoimmune disease. Further, the categorization of NLRX1 as a regulatory NLR offers the potential to intrinsically restore immune tolerance to the gut.
This work was supported by National Institutes of Health Public Service Grant 1R43DK121561.
The online version of this article contains supplemental material.
Abbreviations used in this article:
dextran sulfate sodium
inflammatory bowel disease
PMA (5 ng/ml) and ionomycin (500 ng/ml)
reactive oxygen species
regulatory T cell
All authors are employees of Landos Biopharma. J.B.-R. is a shareholder of Landos Biopharma.